Slominski Andrzej T, Kim Tae-Kang, Janjetovic Zorica, Slominski Radomir M, Ganguli-Indra Gitali, Athar Mohammad, Indra Arup K, Reiter Russel J, Kleszczyński Konrad
Department of Dermatology, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA; Cancer Chemoprevention Program, Comprehensive Cancer Center, The University of Alabama at Birmingham, Birmingham, Alabama, USA; Pathology and Laboratory Medicine Service, VA Medical Center, Birmingham, Alabama, USA.
Department of Dermatology, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
J Invest Dermatol. 2025 Jun;145(6):1345-1360.e2. doi: 10.1016/j.jid.2024.11.012. Epub 2025 Feb 6.
Skin has the capacity to produce and metabolize melatonin into biologically active metabolites. These metabolites exert phenotypic activities through receptor-dependent and receptor-independent action, including direct antioxidant activity, interaction with regulatory proteins, and regulation of mitochondrial function. They can act on G-protein-coupled melatonin receptors (MT1 and MT2) as well as nuclear aryl hydrocarbon receptor and peroxisome proliferator-activated receptor γ receptors. These metabolic pathways, together with receptor- and nonreceptor-mediated phenotypic activities of its intermediates, has been identified as a cutaneous melatoninergic system. Its pharmacological modulation and topical application of melatonin or its metabolites can be used to prevent and treat skin disorders and cutaneous aging.
皮肤有能力将褪黑素生成并代谢为具有生物活性的代谢产物。这些代谢产物通过受体依赖性和非受体依赖性作用发挥表型活性,包括直接抗氧化活性、与调节蛋白的相互作用以及线粒体功能的调节。它们可以作用于G蛋白偶联褪黑素受体(MT1和MT2)以及核芳烃受体和过氧化物酶体增殖物激活受体γ。这些代谢途径,连同其中间体的受体介导和非受体介导的表型活性,已被确定为皮肤褪黑素能系统。其药理学调节以及褪黑素或其代谢产物的局部应用可用于预防和治疗皮肤疾病及皮肤老化。